

Supplementary Table 1. Characteristics of stage II and III colorectal cancer patients from the ACCORD-CRC registry who underwent upfront curative surgical resection from 2000 to 2018

	All patients <i>n</i> = 4033	Included in analysis <i>n</i> = 2767	Not included in analysis <i>n</i> = 1266	P
Age				
Median	70	71	67	<0.001
Range	14-101	18-101	14-99	
Gender				0.370
Male	2189 (54.3%)	1515 (54.8%)	674 (53.2%)	
Female	1844 (45.7%)	1252 (45.3%)	592 (46.8%)	
ECOG status				0.067
0	2191 (54.3%)	1476 (53.3%)	715 (56.5%)	
1-2	1262 (31.3%)	898 (32.5%)	364 (28.8%)	
3-4	103 (2.6%)	72 (2.6%)	31 (2.5%)	
Unknown	477 (11.8%)	321 (11.6%)	156 (12.3%)	
ASA score				0.006
1-2	1877 (46.5%)	1270 (45.9%)	607 (48.0%)	
≥3	1497 (37.1%)	1078 (39.0%)	419 (33.1%)	
Unknown	659 (16.3%)	419 (15.1%)	240 (29.0%)	
Primary tumor location				<0.001
Right colon	1772 (43.9%)	1304 (47.1%)	468 (37.0%)	
Left colon	1708 (42.4%)	1145 (41.4%)	563 (44.5%)	
Rectum	543 (13.5%)	313 (11.3%)	230 (18.2%)	
Unknown	10 (0.3%)	5 (0.2%)	5 (0.4%)	
Campus type				0.279
Public	2900 (71.9%)	2004 (72.4%)	896 (70.8%)	
Private	1133 (28.1%)	763 (27.6%)	370 (29.2%)	
IRSAD				0.052
High (8-10)	1719 (42.6%)	1198 (43.3%)	521 (41.2%)	
Intermediate (5-7)	1406 (34.9%)	967 (35.0%)	439 (34.7%)	
Low (1-4)	864 (21.4%)	562 (20.3%)	302 (23.9%)	
Unknown	44 (1.1%)	40 (1.5%)	4 (0.3%)	
Smoking history				0.119
Current smoker	448 (11.1%)	322 (11.6%)	126 (10.0%)	
Former or never smoker	3407 (84.5%)	2325 (84.0%)	1082 (85.5%)	
Unknown	178 (4.4%)	120 (4.3%)	58 (4.6%)	
Presentation				0.008
Screen-detected	504 (12.5%)	371 (13.4%)	133 (10.5%)	
Other	3342 (82.9%)	2262 (81.8%)	1080 (85.3%)	
Unknown	176 (4.6%)	134 (4.8%)	53 (4.2%)	
Diabetes				0.241
Yes	828 (20.5%)	582 (21.0%)	246 (19.4%)	
No	3103 (76.9%)	2115 (76.4%)	988 (78.0%)	
Unknown	102 (2.5%)	70 (2.5%)	32 (2.5%)	
Stage				<0.001
II	2112 (52.4%)	2112 (76.3%)	0	
III	1921 (47.6%)	655 (23.7%)	1266 (100%)	
Post-operative complications				0.389
Yes	1412 (35.0%)	973 (35.2%)	439 (34.7%)	
No	2184 (54.2%)	1475 (53.3%)	709 (56.0%)	
Unknown	437 (10.8%)	319 (11.5%)	118 (9.3%)	
Adjuvant chemotherapy				
Stage II	346 (16.4%)	346 (16.4%)	N/A	N/A
Stage III	1433 (74.6%)	465 (71.0%)	968 (76.5%)	0.009

ASA; American Society of Anesthesiologists, ECOG; Eastern Co-operative Oncology Group, IRSAD; Index of Relative Socioeconomic Advantage and Disadvantage